Kyorin Licenses Merck’s OAB Drug Vibegron For Japan
This article was originally published in PharmAsia News
Kyorin Pharmaceuticals has entered into a licensing agreement with U.S.-based Merck & Co for the overactive bladder drug vibegron, hoping to expand its product lineup in the urology field.
You may also be interested in...
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. Past cases show the pharma sector is not immune and while it remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions.
Digital Health Roundup, March 2021: Record-Breaking Funding; Exec Chats With Medtronic, Edwards LifeSciences
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news to date.